JPWO2020092467A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020092467A5 JPWO2020092467A5 JP2021523839A JP2021523839A JPWO2020092467A5 JP WO2020092467 A5 JPWO2020092467 A5 JP WO2020092467A5 JP 2021523839 A JP2021523839 A JP 2021523839A JP 2021523839 A JP2021523839 A JP 2021523839A JP WO2020092467 A5 JPWO2020092467 A5 JP WO2020092467A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- car
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000011319 anticancer therapy Methods 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 4
- 230000026683 transduction Effects 0.000 claims 4
- 238000010361 transduction Methods 0.000 claims 4
- 102400001368 Epidermal growth factor Human genes 0.000 claims 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims 3
- 229940116977 epidermal growth factor Drugs 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000000315 cryotherapy Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102000008579 Transposases Human genes 0.000 claims 1
- 108010020764 Transposases Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000000254 ciliated cell Anatomy 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752889P | 2018-10-30 | 2018-10-30 | |
| US62/752,889 | 2018-10-30 | ||
| PCT/US2019/058710 WO2020092467A1 (en) | 2018-10-30 | 2019-10-30 | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512891A JP2022512891A (ja) | 2022-02-07 |
| JPWO2020092467A5 true JPWO2020092467A5 (enExample) | 2022-10-28 |
| JP7548584B2 JP7548584B2 (ja) | 2024-09-10 |
Family
ID=70464551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523839A Active JP7548584B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ７９ｂ抗体およびキメラ抗原レセプターおよびそれらの使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12454574B2 (enExample) |
| EP (1) | EP3873939A4 (enExample) |
| JP (1) | JP7548584B2 (enExample) |
| KR (1) | KR20210098454A (enExample) |
| CN (1) | CN113227145A (enExample) |
| AU (1) | AU2019370276A1 (enExample) |
| CA (1) | CA3118337A1 (enExample) |
| WO (1) | WO2020092467A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020092467A1 (en) | 2018-10-30 | 2020-05-07 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
| EP4142778A4 (en) * | 2020-04-30 | 2024-06-05 | Board of Regents, The University of Texas System | ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| MX2023014352A (es) * | 2021-06-01 | 2024-03-14 | Janssen Biotech Inc | Anticuerpos antiidiotipicos contra anticuerpos anti-cd79b. |
| WO2024026284A2 (en) * | 2022-07-25 | 2024-02-01 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| TWI894742B (zh) * | 2022-12-29 | 2025-08-21 | 美商Ｌｔｚ治療股份有限公司 | 抗CD79b抗體及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| CA2882022A1 (en) | 2003-09-11 | 2005-03-24 | Walter Newman | Monoclonal antibodies against hmgb1 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| MX382301B (es) | 2012-12-24 | 2025-03-13 | Abbvie Inc | Proteinas de union al receptor de prolactina y usos de las mismas. |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| ES2744540T3 (es) * | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anticuerpos anti-CD79b y procedimientos de uso |
| US20180057595A1 (en) | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
| CA2984624A1 (en) * | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| CN107708741A (zh) | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| WO2017120280A1 (en) * | 2016-01-06 | 2017-07-13 | Virginia Tech Intellectual Properties, Inc. | Antigen targeting to porcine langerin |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN110799640B (zh) | 2017-06-07 | 2024-11-12 | 综合医院公司 | 表达嵌合抗原受体的t细胞 |
| EP3658185A4 (en) | 2017-07-28 | 2021-07-14 | Phanes Therapeutics, Inc. | ANTI-TIM-3 ANTIBODIES AND USES THEREOF |
| US20230192845A1 (en) | 2017-08-11 | 2023-06-22 | Blink Biomedical Sas | Cd96-binding agents as immunomodulators |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CN109265565B (zh) | 2018-10-10 | 2021-06-01 | 苏州大学 | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 |
| WO2020092467A1 (en) | 2018-10-30 | 2020-05-07 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
-
2019
- 2019-10-30 WO PCT/US2019/058710 patent/WO2020092467A1/en not_active Ceased
- 2019-10-30 CA CA3118337A patent/CA3118337A1/en active Pending
- 2019-10-30 US US17/309,144 patent/US12454574B2/en active Active
- 2019-10-30 EP EP19878006.6A patent/EP3873939A4/en active Pending
- 2019-10-30 KR KR1020217016410A patent/KR20210098454A/ko not_active Withdrawn
- 2019-10-30 CN CN201980085366.4A patent/CN113227145A/zh active Pending
- 2019-10-30 AU AU2019370276A patent/AU2019370276A1/en active Pending
- 2019-10-30 JP JP2021523839A patent/JP7548584B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnamurthy et al. | Bispecific antibodies for cancer therapy: a review | |
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| Nunez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| Kontermann | Recombinant bispecific antibodies for cancer therapy | |
| JP2019523630A5 (enExample) | ||
| CN115232209B (zh) | 靶向gprc5d的抗体及其用途 | |
| CN110551221A (zh) | 一种双特异性抗体及其制备方法与应用 | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| EP4050031A1 (en) | Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereof | |
| CN117836328A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| CN113039208A (zh) | 一种抗pd-l1抗原结合蛋白及其应用 | |
| WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
| CN114539402A (zh) | 靶向Claudin18.2的抗体及其用途 | |
| JPWO2020092467A5 (enExample) | ||
| Hollander | Bispecific antibodies for cancer therapy | |
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| CN119894930A (zh) | 一种双特异性抗体及其应用 | |
| JPWO2022008646A5 (enExample) | ||
| JPWO2023079102A5 (enExample) | ||
| EP4603509A1 (en) | Multifunctional recombinant antibody, and preparation method and use therefor | |
| JPWO2023062604A5 (enExample) | ||
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| US20220127360A1 (en) | Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof | |
| WO2024253596A1 (en) | Her2 chimeric antigen receptor secreting |